CVS Health Expands GLP-1 Access with Lilly Collaboration and $29 MinuteClinic Visits
CVS sits 71% above its 52-week low of $61.35.
Summary
CVS Health is revamping its weight management program to capture more of the booming GLP-1 market. The company is collaborating with Eli Lilly to offer Zepbound and Foundayo patients transparent pricing and app-based access by early Q4 2026, complementing existing Wegovy availability. MinuteClinic online weight loss visits are now $29 with no membership fee, making it the most affordable option and connecting patients to same-day pickup at 9,000 pharmacies. This builds on the June expansion of GLP-1 support and the May restoration of Zepbound coverage at Caremark, signaling an aggressive push to become a one-stop shop for weight loss care. The integrated model — combining telehealth, pharmacy, and pharmacist support — could drive foot traffic and prescription volume, strengthening CVS's competitive position against digital health rivals. With Medicare Advantage rates projected to rise over 5% for 2026 and the recent Omnicare sale closing, this consumer-focused initiative adds a growth lever amid ongoing legal and regulatory challenges.
At the time of this announcement, CVS was trading at $104.82 on NYSE in the Trade & Services sector, with a market capitalization of approximately $133.2B. The 52-week trading range was $61.35 to $110.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.